Notice NOT-MH-20-067 from the NIH Guide for Grants and Contracts

Notice NOT-HG-20-050 from the NIH Guide for Grants and Contracts

Competitive Salary: EMBL: Software Developer Location: EMB Cambridge, Cambridgeshire, England

Notice NOT-OD-20-122 from the NIH Guide for Grants and Contracts

Notice NOT-MH-20-070 from the NIH Guide for Grants and Contracts

Notice NOT-DA-20-063 from the NIH Guide for Grants and Contracts

Or equivalent in genomics, bioinformatics, data science, statistics, or a related field, with a strong publication record.
From Resolution Bioscience - Wed, 08 Jul 2020 03:24:02 GMT - View all Kirkland, WA jobs

Candidates should have experience working with common computer applications used in lab operations and data analysis (Word, Powerpoint, Excel, etc.).
From University of Wisconsin–Madison - Tue, 07 Jul 2020 18:57:36 GMT - View all Madison, WI jobs

F. Hoffmann-La Roche AG: As a (Associate)/Group Director within our Personalized HealthCare function you will be responsible for the data science strategies, and lead a team Switzerland (CH)

Competitive Salary: EMBL: Senior Software Developer Location: Cambridge, Cambridgeshire, England

Competitive Salary: EMBL: Bioinformatician - WormBase Location: Cambridge, Cambridgeshire, England

Competitive Salary: EMBL: Bioinformatician Location: EMBL- Cambridge, Cambridgeshire, England

Notice NOT-NS-20-092 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-20-011 from the NIH Guide for Grants and Contracts. Acute kidney injury (AKI) is associated with high morbidity, including increased risk of chronic kidney disease (CKD), end-stage kidney disease (ESKD), cardiovascular disease, and mortality. Severity, duration, and frequency of episodes of AKI as well as age, pre-existing CKD, and other comorbidities are associated with greater risks of CKD progression and death. There is limited evidence to inform recommendations for processes of care or therapeutic interventions targeting progression of kidney disease and the associated morbidity and mortality in AKI survivors. This is a missed opportunity to prevent chronic disease and premature death. The Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) consortium composed of 3 to 4 Clinical Centers (CCs) and a Scientific and Data Research Center (SDRC) will develop and test interventions that aim to reduce morbidity compared with usual care in AKI survivors.

Funding Opportunity RFA-DK-20-012 from the NIH Guide for Grants and Contracts. Acute kidney injury (AKI) is associated with high morbidity, including increased risk of chronic kidney disease (CKD), end-stage kidney disease (ESKD), cardiovascular disease, and mortality. Severity, duration, and frequency of episodes of AKI as well as age, pre-existing CKD, and other comorbidities are associated with greater risks of CKD progression and death. There is limited evidence to inform recommendations for processes of care or therapeutic interventions targeting progression of kidney disease and the associated morbidity and mortality in AKI survivors. This is a missed opportunity to prevent chronic disease and premature death. The 'Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) consortium, composed of 3 to 4 Clinical Centers (CCs) and a Scientific and Data Research Center (SDRC), will develop and test interventions that aim to reduce morbidity compared with usual care in Stage 2 and 3 AKI survivors.

Notice NOT-CA-20-084 from the NIH Guide for Grants and Contracts

Notice NOT-NS-20-091 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-080 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-20-253 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for NIH Countermeasures Against Chemical Threats (CounterACT) exploratory/developmental (R21) projects. The mission of the NIH CounterACT program is to foster and support research that will advance development of new and improved therapeutics to mitigate the health effects of chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The scope of the research includes basic toxicological research on the chemical threat for the purpose of target and therapeutic hit identification, hit validation, lead optimization, and demonstration of in vivo ADME/Tox and efficacy. Projects supported by this FOA are expected to generate preliminary data that would facilitate the development of competitive applications for more extensive support from the NIH CounterACT Cooperative Agreement programs or other related initiatives.

Funding Opportunity RFA-CA-20-037 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities.